Gerinnungsaktive Therapeutika

Zusammenfassung

Gerinnungsaktive Therapeutika (AT, FFP, PPSB, FXIII, rFVIIa) werden auf der Intensivstation häufig eingesetzt.

Indikationen, Dosierung, spezifische Effekte und Nebenwirkungen sind dabei zu beachten.

Summary

Replacement therapy of coagulation factor preparations (AT, FFP, PPSB, FXIII, rFVIIa) are frequently used on the Intensive Care Units.

Indications, dosage, specific effects and side effects have to be considered.

Schlüsselwörter

Antithrombin - Fresh-frozen-Plasma - FVIIa - FXIII

Keywords

Antithrombin - fresh frozen plasma - FVIIa - FXIII

• Literatur

• 1 Al Douri M, Shafi T, Al Khudairi D. et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 01) 121-7.
• 2 Ameri A, Stolte S. Correlation of activated clotting time (ACT) with rFVIIa infusion and clinical efficacy in a patient with Glanzmann Thrombasthenia and platelet alloantibodies. Thromb Haemost 2002; 87: 1084.
• 3 Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74 (Suppl. 01) 219-23.
• 4 Berntorp E. Recombinant FVIIa in the treatment of warfarin bleeding. Sem Thromb Hemost 2000; 26: 433-5.
• 5 Comp PC. Control of coagulation reactions. In: Wiliams WJ, Beutler E, Erslev AJ. et al. (eds). Hematology. 4th International Edition. New York: McGraw-Hill; 1991: 1304-12.
• 6 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-30.
• 7 Erhardtsen E. Ongoing NovoSeven® trials. Intensive Care Med 2002; 28: 248-55.
• 8 Fourrier F, Chopin C, Huart JJ. et al. Double-blind placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-8.
• 9 Friederich PW, Geerdink H, Keller TT. et al. Novel application of recombinant factor VIIa: the effect of the administration of recombinant activated VII (NovoSeven) on perioperative blood loos in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Infus Ther Transfus Med 2001; 28: 112-3.
• 10 Gerotziafas GT, Zervas C, Gavrielidis G. et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and lifethreatening haemorrhage. Am J Hematol 2002; 69: 219-22.
• 11 Grossmann RE, Geisen U, Schwender S. et al. Continuous infusion of recombinant factor VIIa (NovoSeven®) in the treatment of a patient with Type III von-Willebrand’s disease and alloantibodies against von-Willebrand factor. Thromb Haemost 2000; 83: 633-4.
• 12 Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemostas 1997; 78: 1463-7.
• 13 Hedner U, Erhardtsen E. Potential role for rhFVIIa in transfusion medicine. Transfusion 2002; 42: 114-24.
• 14 Hellstern P, Beeck H, Fellhauer A. et al. for the PCC Study Group. Factor VII and Activated-Factor-VII Content of Prothrombin Complex Concentrates. Vox Sang 1997; 73: 155-61.
• 15 Heuer L, Blumenberg D. Rekombinanter Faktor VIIa (NovoSeven®). Ein Überblick über aktuelle und mögliche zukünftige Indikationen. Anaesthesist 2002; 51: 388-99.
• 16 Jurlander B, Thim L, Klausen N. et al. Recombinant activated factor VII (rhFVIIa): Characterisation, manufacturing and clinical development. Sem Thromb Haemostas 2001; 27: 373-83.
• 17 Kenet G, Walden R, Eldad A. et al. Surgical intervention failed to stop life-threatening bleeding caused by injury complicated by severe coagulopathy. Administration of recombinant factor VIIa immediately corrected the coagulopathy and stopped bleeding. Lancet 1999; 345: 1879.
• 18 Klein H, Dodd RY, Czik WH. et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38: 102-7.
• 19 Köhler M. et al. Virusinaktiviertes Plasma. Infusionsther Transfusionsmed 1994; 21 (Suppl. 01) 73-6.
• 20 Lane DA, Bayston T, Olds RJ. et al. Antithrombin mutation database: 2nd (1977) update. Thromb Haemost 1997; 77: 197-211.
• 21 Lucia JF, Aguilar C, Orna E. et al. Successful outcome of a cirrhotic patient with postoperative haematuria treated with a single high dose of recombinant factor VIIa. Haemophilia 2001; 7: 600-2.
• 22 Monroe DM, Hoffmann M, Oliver JA. et al. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinol 1998; 9 (Suppl. 01) 15-20.
• 23 Muszek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: Structure and function. Thromb Res 19999 94: 271-305.
• 24 Nijenhuis AVM, van Bergeijk L, Huijgens PC. et al. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematology 2004; 89: ECR 14.
• 25 O’Shaughnessy DF, Atterbury C, Bolton Maggs P. et al. Guidelines for the use of fresh-frozen-plasma, cryoprecipitate and cryosupernatant. The British Society for Haematology 2004; 126: 11-28.
• 26 Oldenburg J, Hertfelder HJ, Brackmann HH. et al. Eigenschaften und Indikationen von PPSB-Konzentraten unter besonderer Berücksichtigung der Qualitätssicherung sowie flankierender therapeutischer Maßnahmen. Infusionsther Transfusionsmed 1996; 23: 271-80.
• 27 Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Current Opin Hematol 2001; 8: 312-8.
• 28 Preston FE, Laidlaw ST, Sampson B. et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116: 619-24.
• 29 Römisch J, Bonik K, Diehl KH. et al. Vergleichende In-vitro-Untersuchung von drei Prothrombinkomplex-Konzentraten (PPSB). Med Welt 1997; 48: 205-11.
• 30 Rosenberg RD. Actions and interaction of antithrombin and heparin. N Engl J Med 1975; 292: 146-51.
• 31 Scharrer I. on behalf of the German NovoSeven Study Group. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
• 32 Schregel W, Straub H, Wölk G. et al. Erfolgreiche Therapie einer Verbrauchskoagulopathie bei EPH-Gestose mit mehrfachem Organversagen. Anaesth Intensivther Notfallmed 1984; 19: 201-3.
• 33 Sutor AH, Bruhn HD, Schreiber R. et al. Thrombosen im Kindesalter. Hämostaseologie 1992; 12: 82-93.